CTMX vs. MTA
Compare and contrast key facts about CytomX Therapeutics, Inc. (CTMX) and Metalla Royalty & Streaming Ltd. (MTA).
Performance
CTMX vs. MTA - Performance Comparison
Loading graphics...
CTMX vs. MTA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CTMX CytomX Therapeutics, Inc. | 10.33% | 313.59% | -33.55% | -3.13% | -63.05% | -33.89% | -21.18% | -44.97% | -28.47% | 20.56% |
MTA Metalla Royalty & Streaming Ltd. | -14.78% | 209.96% | -18.51% | -36.95% | -29.15% | -44.82% | 133.14% | 122.65% | 20.19% | 6.75% |
Fundamentals
CTMX:
$799.88M
MTA:
$614.14M
CTMX:
-$0.11
MTA:
-$0.06
CTMX:
9.55
MTA:
42.20
CTMX:
8.08
MTA:
1.78
CTMX:
$76.20M
MTA:
$14.66M
CTMX:
$75.69M
MTA:
$12.13M
CTMX:
-$19.39M
MTA:
$2.86M
Returns By Period
In the year-to-date period, CTMX achieves a 10.33% return, which is significantly higher than MTA's -14.78% return.
CTMX
- 1D
- 6.58%
- 1M
- -12.48%
- YTD
- 10.33%
- 6M
- 47.34%
- 1Y
- 639.23%
- 3Y*
- 46.01%
- 5Y*
- -9.80%
- 10Y*
- -9.91%
MTA
- 1D
- 9.41%
- 1M
- -26.74%
- YTD
- -14.78%
- 6M
- 4.41%
- 1Y
- 131.82%
- 3Y*
- 6.03%
- 5Y*
- -6.27%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CTMX vs. MTA — Risk / Return Rank
CTMX
MTA
CTMX vs. MTA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CytomX Therapeutics, Inc. (CTMX) and Metalla Royalty & Streaming Ltd. (MTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CTMX | MTA | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.81 | 2.46 | +1.35 |
Sortino ratioReturn per unit of downside risk | 4.71 | 2.86 | +1.85 |
Omega ratioGain probability vs. loss probability | 1.61 | 1.36 | +0.25 |
Calmar ratioReturn relative to maximum drawdown | 15.76 | 3.78 | +11.98 |
Martin ratioReturn relative to average drawdown | 36.65 | 15.14 | +21.51 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| CTMX | MTA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.81 | 2.46 | +1.35 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.07 | -0.12 | +0.05 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.09 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.08 | 0.28 | -0.36 |
Correlation
The correlation between CTMX and MTA is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
CTMX vs. MTA - Dividend Comparison
Neither CTMX nor MTA has paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
CTMX CytomX Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MTA Metalla Royalty & Streaming Ltd. | 0.00% | 0.00% | 0.00% | 0.75% | 0.00% | 0.00% | 0.10% | 0.75% | 2.16% |
Drawdowns
CTMX vs. MTA - Drawdown Comparison
The maximum CTMX drawdown since its inception was -98.74%, which is greater than MTA's maximum drawdown of -81.73%. Use the drawdown chart below to compare losses from any high point for CTMX and MTA.
Loading graphics...
Drawdown Indicators
| CTMX | MTA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.74% | -81.73% | -17.01% |
Max Drawdown (1Y)Largest decline over 1 year | -41.14% | -33.04% | -8.10% |
Max Drawdown (5Y)Largest decline over 5 years | -95.65% | -78.00% | -17.65% |
Max Drawdown (10Y)Largest decline over 10 years | -98.74% | — | — |
Current DrawdownCurrent decline from peak | -86.27% | -49.33% | -36.94% |
Average DrawdownAverage peak-to-trough decline | -70.40% | -41.29% | -29.11% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.69% | 8.24% | +9.45% |
Volatility
CTMX vs. MTA - Volatility Comparison
CytomX Therapeutics, Inc. (CTMX) has a higher volatility of 53.47% compared to Metalla Royalty & Streaming Ltd. (MTA) at 20.25%. This indicates that CTMX's price experiences larger fluctuations and is considered to be riskier than MTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| CTMX | MTA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 53.47% | 20.25% | +33.22% |
Volatility (6M)Calculated over the trailing 6-month period | 74.27% | 40.20% | +34.07% |
Volatility (1Y)Calculated over the trailing 1-year period | 169.33% | 54.05% | +115.28% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 142.15% | 53.32% | +88.83% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.35% | 57.25% | +54.10% |
Financials
CTMX vs. MTA - Financials Comparison
This section allows you to compare key financial metrics between CytomX Therapeutics, Inc. and Metalla Royalty & Streaming Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities